Eli Lilly Q1 revenue rises 56% to $19.8 billion; full-year guidance raised
Eli Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% from a year earlier, and reported EPS of $8.26 versus $3.06. The company raised its full-year 2026 revenue guidance to $82.0 billion to $85.0 billion and its non-GAAP EPS guidance to $35.50 to $37.00, which matters to shareholders because it raises the company's own outlook for the year.
Key points
- Q1 2026 revenue was $19.8 billion, up 56% from $12.7 billion, driven by a 65% increase in volume, partly offset by a 13% decrease from lower realized prices.
- Reported EPS was $8.26 versus $3.06; non-GAAP EPS was $8.55 versus $3.34.
- Full-year 2026 revenue guidance rose to $82.0 billion to $85.0 billion from $80 billion to $83 billion; non-GAAP EPS guidance rose to $35.50 to $37.00 from $33.50 to $35.00.
- Reported gross margin was 81.9% of revenue, down 0.6 percentage points, primarily due to lower realized prices.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.